Abstract
Modafinil (MOD) it has to be considered as a wake-inducing drug to treat sleep disorders such as excessive sleepiness in narcolepsy, shift-work disorder, and obstructive/sleep apnea syndrome. Current evidence suggests that MOD induces waking involving the dopamine D1 receptor. However, little is known regarding the molecular elements linked in the wake-promoting actions of MOD. Since the D1 receptor activates the mitogen-activated protein kinase (MAP-K) cascade, it raises the interesting possibility that effects of MOD would depend upon the activation of MAP-K. Here we tested the expression of MAP-K in hypothalamus as well as pons after the microinjection of MOD (10 or 20μg/1μL) in rats into anterior hypothalamus, a wake-inducing brain area. Intrahypothalamic injections of MOD promoted MAP-K phosphorylation in hypothalamus and pons. Taken together, these results suggest that the wake-inducing compound MOD promotes the MAP-K phosphorylation.
Keywords: Dopamine, hypothalamus, modafinil, narcolepsy, protein, pons, rat, wakefulness, western blot.
CNS & Neurological Disorders - Drug Targets
Title:Intrahypothalamic Administration of Modafinil Increases Expression of MAP-Kinase in Hypothalamus and Pons in Rats
Volume: 14 Issue: 4
Author(s): Alwin Poot-Ake, Stephanie Mijangos-Moreno, Danielle Manjarrez-Martin, Ramses Jimenez-Moreno, Pedro R. Aquino-Hernandez, Elda Pacheco-Pantoja, Oscar Arias-Carrion, Andrea Sarro-Ramirez, Gloria Arankowsky-Sandoval and Eric Murillo-Rodriguez
Affiliation:
Keywords: Dopamine, hypothalamus, modafinil, narcolepsy, protein, pons, rat, wakefulness, western blot.
Abstract: Modafinil (MOD) it has to be considered as a wake-inducing drug to treat sleep disorders such as excessive sleepiness in narcolepsy, shift-work disorder, and obstructive/sleep apnea syndrome. Current evidence suggests that MOD induces waking involving the dopamine D1 receptor. However, little is known regarding the molecular elements linked in the wake-promoting actions of MOD. Since the D1 receptor activates the mitogen-activated protein kinase (MAP-K) cascade, it raises the interesting possibility that effects of MOD would depend upon the activation of MAP-K. Here we tested the expression of MAP-K in hypothalamus as well as pons after the microinjection of MOD (10 or 20μg/1μL) in rats into anterior hypothalamus, a wake-inducing brain area. Intrahypothalamic injections of MOD promoted MAP-K phosphorylation in hypothalamus and pons. Taken together, these results suggest that the wake-inducing compound MOD promotes the MAP-K phosphorylation.
Export Options
About this article
Cite this article as:
Poot-Ake Alwin, Mijangos-Moreno Stephanie, Manjarrez-Martin Danielle, Jimenez-Moreno Ramses, Aquino-Hernandez R. Pedro, Pacheco-Pantoja Elda, Arias-Carrion Oscar, Sarro-Ramirez Andrea, Arankowsky-Sandoval Gloria and Murillo-Rodriguez Eric, Intrahypothalamic Administration of Modafinil Increases Expression of MAP-Kinase in Hypothalamus and Pons in Rats, CNS & Neurological Disorders - Drug Targets 2015; 14 (4) . https://dx.doi.org/10.2174/1871527314666150429113609
DOI https://dx.doi.org/10.2174/1871527314666150429113609 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Gap Junctions as Targets for Cancer Chemoprevention and Chemotherapy
Current Drug Targets Gold(III) Complexes in the Oncological Preclinical Arena: From Aminoderivatives to Peptidomimetics
Current Topics in Medicinal Chemistry Potential Anticancer Effect of Carvacrol Codrugs on Human Glioblastoma Cells
Current Drug Delivery QSAR and Docking Studies of N-hydroxy Urea Derivatives as Flap Endonuclease-1 Inhibitors
Current Computer-Aided Drug Design Harnessing the Natural Pool of Polyketide and Non-ribosomal Peptide Family: A Route Map towards Novel Drug Development
Current Molecular Pharmacology The Caveolin-1 Connection to Cell Death and Survival
Current Molecular Medicine Nitric Oxide and Dietary Factors: Part V Summary/Conclusion and References
Vascular Disease Prevention (Discontinued) Small Molecule Toxins Targeting Tumor Receptors
Current Pharmaceutical Design Inhibition of Sphingomyelin Hydrolysis: Targeting the Lipid Mediator Ceramide as a Key Regulator of Cellular Fate
Current Medicinal Chemistry Design, Synthesis and Evaluation of 8-Thiosubstituted 1,3,7- Trimethylxanthine Hydrazones with In-vitro Neuroprotective and MAO-B Inhibitory Activities
Medicinal Chemistry The ALK Gene, An Attractive Target for Inhibitor Development
Current Topics in Medicinal Chemistry Mechanisms of HIV-1 Tat Neurotoxicity via CDK5 Translocation and Hyper-Activation: Role in HIV-Associated Neurocognitive Disorders
Current HIV Research Role of Netrin-1 Beyond the Brain: From Biomarker of Tissue Injury to Therapy for Inflammatory Diseases
Recent Patents on Biomarkers The Effects of 1,3,5-trisubstituted Indole Derivatives on Cell Growth, Apoptosis and MMP-2/9 mRNA Expression of MCF-7 Human Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Cholesterol and Apoe: A Target for Alzheimers Disease Therapeutics
Current Drug Targets - CNS & Neurological Disorders Non-Homologous DNA End Joining in Anticancer Therapy
Current Cancer Drug Targets Biological and Clinical Implications of Clonal Heterogeneity and Clonal Evolution in Multiple Myeloma
Current Cancer Therapy Reviews Protein Kinase C Pharmacology: Perspectives on Therapeutic Potentials as Antidementic and Cognitive Agents
Recent Patents on CNS Drug Discovery (Discontinued) New Molecular Avenues in Parkinson ’ s Disease Therapy
Current Topics in Medicinal Chemistry Structure and Mechanism of Action of Tau Aggregation Inhibitors
Current Alzheimer Research